Cboe US - Delayed Quote USD

iShares U.S. Home Construction ETF (ITB)

118.08 -0.02 (-0.02%)
At close: November 13 at 4:00 PM EST
118.00 -0.08 (-0.07%)
Pre-Market: 5:42 AM EST
Loading Chart for ITB
DELL
  • Previous Close 118.10
  • Open 119.12
  • Bid 113.00 x 800
  • Ask 121.52 x 1400
  • Day's Range 117.97 - 120.13
  • 52 Week Range 85.67 - 129.89
  • Volume 2,511,667
  • Avg. Volume 1,645,370
  • Net Assets 3.36B
  • NAV 118.99
  • PE Ratio (TTM) 13.11
  • Yield 0.39%
  • YTD Daily Total Return 18.35%
  • Beta (5Y Monthly) 1.56
  • Expense Ratio (net) 0.39%

The index measures the performance of the home construction sector of the U.S. equity market, as defined by the index provider. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. It is non-diversified.

iShares

Fund Family

Consumer Cyclical

Fund Category

3.36B

Net Assets

2006-05-01

Inception Date

Performance Overview: ITB

View More

Trailing returns as of 11/7/2024. Category is Consumer Cyclical.

YTD Return

ITB
18.35%
Category
9.99%
 

1-Year Return

ITB
48.11%
Category
33.69%
 

3-Year Return

ITB
18.08%
Category
0.34%
 

People Also Watch

Holdings: ITB

View More

Top 10 Holdings (65.72% of Total Assets)

SymbolCompany% Assets
DHI
D.R. Horton, Inc. 14.14%
LEN
Lennar Corporation 11.74%
NVR
NVR, Inc. 8.04%
PHM
PulteGroup, Inc. 7.67%
HD
The Home Depot, Inc. 4.80%
LOW
Lowe's Companies, Inc. 4.78%
SHW
The Sherwin-Williams Company 4.36%
TOL
Toll Brothers, Inc. 4.29%
BLD
TopBuild Corp. 3.02%
BLDR
Builders FirstSource, Inc. 2.89%

Sector Weightings

SectorITB
Industrials   18.55%
Real Estate   0.70%
Technology   0.00%
Utilities   0.00%
Energy   0.00%
Healthcare   0.00%

Recent News: ITB

View More

Research Reports: ITB

View More
  • Biopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • Biopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • BUY as company raises earnings guidance

    Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.

    Rating
    Price Target
     
  • Biogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     

Related Tickers